Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-071375
Filing Date
2025-05-14
Accepted
2025-05-14 16:06:47
Documents
54
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q maze-20250331.htm   iXBRL 10-Q 1947332
2 EX-31.1 maze-ex31_1.htm EX-31.1 14691
3 EX-32.1 maze-ex32_1.htm EX-32.1 11592
  Complete submission text file 0000950170-25-071375.txt   6418209

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT maze-20250331.xsd EX-101.SCH 745787
56 EXTRACTED XBRL INSTANCE DOCUMENT maze-20250331_htm.xml XML 947392
Mailing Address 171 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CA 94080 6508505070
Maze Therapeutics, Inc. (Filer) CIK: 0001842295 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-42490 | Film No.: 25945418
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)